Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Global opioid agonist treatment: a review of clinical practices by country.
Jin H, Marshall BDL, Degenhardt L, Strang J, Hickman M, Fiellin DA, Ali R, Bruneau J, Larney S. Jin H, et al. Among authors: bruneau j. Addiction. 2020 Dec;115(12):2243-2254. doi: 10.1111/add.15087. Epub 2020 May 19. Addiction. 2020. PMID: 32289189 Free PMC article. Review.
Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
Jutras-Aswad D, Le Foll B, Ahamad K, Lim R, Bruneau J, Fischer B, Rehm J, Wild TC, Wood E, Brissette S, Gagnon L, Fikowski J, Ledjiar O, Masse B, Socias ME; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. Jutras-Aswad D, et al. Among authors: bruneau j. Am J Psychiatry. 2022 Oct;179(10):726-739. doi: 10.1176/appi.ajp.21090964. Epub 2022 Jun 15. Am J Psychiatry. 2022. PMID: 35702828 Clinical Trial.
Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.
Socias ME, Wood E, Le Foll B, Lim R, Choi JC, Mok WY, Bruneau J, Rehm J, Wild TC, Bozinoff N, Hassan A, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. Socias ME, et al. Among authors: bruneau j. Addiction. 2022 Oct;117(10):2662-2672. doi: 10.1111/add.15954. Epub 2022 Jun 17. Addiction. 2022. PMID: 35712892 Free PMC article. Clinical Trial.
Co-Constructing a Community-Based Telemedicine Program for People With Opioid Use Disorder During the COVID-19 Pandemic: Lessons Learned and Implications for Future Service Delivery.
Høj SB, de Montigny C, Chougar S, Léandre R, Beauchemin-Nadeau MÈ, Boyer-Legault G, Goyette A, Lamont SK, Bruneau J. Høj SB, et al. Among authors: bruneau j. JMIR Public Health Surveill. 2023 Jul 26;9:e39236. doi: 10.2196/39236. JMIR Public Health Surveill. 2023. PMID: 37494097 Free PMC article.
Comparative Analysis of Instrumental Variables on the Assignment of Buprenorphine/Naloxone or Methadone for the Treatment of Opioid Use Disorder.
Homayra F, Enns B, Min JE, Kurz M, Bach P, Bruneau J, Greenland S, Gustafson P, Karim ME, Korthuis PT, Loughin T, MacLure M, McCandless L, Platt RW, Schnepel K, Shigeoka H, Siebert U, Socias E, Wood E, Nosyk B. Homayra F, et al. Among authors: bruneau j. Epidemiology. 2024 Mar 1;35(2):218-231. doi: 10.1097/EDE.0000000000001697. Epub 2023 Jan 30. Epidemiology. 2024. PMID: 38290142
A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder.
El Hage C, Ghabrash MF, Dubreucq S, Brissette S, Lespérance F, Lespérance P, Ouellet-Plamondon C, Bruneau J, Jutras-Aswad D. El Hage C, et al. Among authors: bruneau j. Int Clin Psychopharmacol. 2018 Sep;33(5):268-273. doi: 10.1097/YIC.0000000000000223. Int Clin Psychopharmacol. 2018. PMID: 29738425 Clinical Trial.
455 results